These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18821746)

  • 1. Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening.
    Markt P; Petersen RK; Flindt EN; Kristiansen K; Kirchmair J; Spitzer G; Distinto S; Schuster D; Wolber G; Laggner C; Langer T
    J Med Chem; 2008 Oct; 51(20):6303-17. PubMed ID: 18821746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds.
    Nevin DK; Peters MB; Carta G; Fayne D; Lloyd DG
    J Med Chem; 2012 Jun; 55(11):4978-89. PubMed ID: 22582973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophore modeling and parallel screening for PPAR ligands.
    Markt P; Schuster D; Kirchmair J; Laggner C; Langer T
    J Comput Aided Mol Des; 2007; 21(10-11):575-90. PubMed ID: 17960326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity landscape modeling of PPAR ligands with dual-activity difference maps.
    Méndez-Lucio O; Pérez-Villanueva J; Castillo R; Medina-Franco JL
    Bioorg Med Chem; 2012 Jun; 20(11):3523-32. PubMed ID: 22564380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview on biological mechanisms of PPARs.
    Kota BP; Huang TH; Roufogalis BD
    Pharmacol Res; 2005 Feb; 51(2):85-94. PubMed ID: 15629253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists.
    Mahindroo N; Peng YH; Lin CH; Tan UK; Prakash E; Lien TW; Lu IL; Lee HJ; Hsu JT; Chen X; Liao CC; Lyu PC; Chao YS; Wu SY; Hsieh HP
    J Med Chem; 2006 Oct; 49(21):6421-4. PubMed ID: 17034149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isoxazolyl-serine-based agonists of peroxisome proliferator-activated receptor: design, synthesis, and effects on cardiomyocyte differentiation.
    Wei ZL; Petukhov PA; Bizik F; Teixeira JC; Mercola M; Volpe EA; Glazer RI; Willson TM; Kozikowski AP
    J Am Chem Soc; 2004 Dec; 126(51):16714-5. PubMed ID: 15612696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological evaluation and structural insights for design of subtype-selective peroxisome proliferator activated receptor-α (PPAR-α) agonists.
    Gangwal RP; Damre MV; Das NR; Sharma SS; Sangamwar AT
    Bioorg Med Chem Lett; 2015 Jan; 25(2):270-5. PubMed ID: 25491112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPARs as therapeutic targets in cardiovascular disease.
    van Bilsen M; van Nieuwenhoven FA
    Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR) γ partial agonists.
    Kaserer T; Obermoser V; Weninger A; Gust R; Schuster D
    Eur J Med Chem; 2016 Nov; 124():49-62. PubMed ID: 27560282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications.
    Mirza AZ; Althagafi II; Shamshad H
    Eur J Med Chem; 2019 Mar; 166():502-513. PubMed ID: 30739829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study.
    Salam NK; Huang TH; Kota BP; Kim MS; Li Y; Hibbs DE
    Chem Biol Drug Des; 2008 Jan; 71(1):57-70. PubMed ID: 18086153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Important pharmacophoric features of pan PPAR agonists: common chemical feature analysis and virtual screening.
    Sundriyal S; Bharatam PV
    Eur J Med Chem; 2009 Sep; 44(9):3488-95. PubMed ID: 19268404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Evaluation of Gemcabene and Peroxisome Proliferator-Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease.
    Bisgaier CL; Oniciu DC; Srivastava RAK
    J Cardiovasc Pharmacol; 2018 Jul; 72(1):3-10. PubMed ID: 29621036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPARs: therapeutic targets for metabolic disease.
    Berger JP; Akiyama TE; Meinke PT
    Trends Pharmacol Sci; 2005 May; 26(5):244-51. PubMed ID: 15860371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators.
    Zoete V; Grosdidier A; Michielin O
    Biochim Biophys Acta; 2007 Aug; 1771(8):915-25. PubMed ID: 17317294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
    Brown JD; Plutzky J
    Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands.
    Merk D; Lamers C; Weber J; Flesch D; Gabler M; Proschak E; Schubert-Zsilavecz M
    Bioorg Med Chem; 2015 Feb; 23(3):499-514. PubMed ID: 25583100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Ligand Screening Tool Using Full-Length Human Peroxisome Proliferator-Activated Receptor-Expressing Cell Lines to Ameliorate Metabolic Syndrome.
    Tachibana K; Ishimoto K; Takahashi R; Kadono H; Awaji T; Yuzuriha T; Tanaka T; Hamakubo T; Sakai J; Kodama T; Aoki S; Doi T
    Chem Pharm Bull (Tokyo); 2019; 67(3):199-202. PubMed ID: 30827999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.